Under the circumstances that there is no study specialized for PD-1/PD-L1-related myocarditis, this review has summarized the current cohort studies, case reports, or case series that focus on PD-1/PD-L1 inhibitors or have a large proportion of PD-1/PD-L1 inhibitors in immune checkpoint inhibitor treatment, with the proportion ranging from 63 to 86% (Escudier et al., 2017; Mahmood et al., 2018; Salem et al., 2018; Wang et al., 2018; Awadalla et al., 2020). This evidence concerns the gene CD274 and myocarditis.